(Q44429171)

English

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

scientific article published on October 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

1

object named as

Sergio Giralt

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

David G. Maloney

9

object named as

David Maloney

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Richard E Champlin

14

object named as

Richard Champlin

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Donald Podoloff

4

object named as

Donald Podoloff

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

12

object named as

Hazel Breitz

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Raymond Alexanian

7

object named as

Raymond Alexanian

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

William Bensinger

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Mark Goodman

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Janet Eary

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Richard Wendt

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Donna Weber

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Leona Holmberg

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Joseph Rajandran

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Richard Ghalie

13

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

David Maloney

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730103

30 December 2023

Richard Champlin

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730103

30 December 2023

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 October 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12730103

30 December 2023

full work available at URL

https://ashpublications.org/blood/article-pdf/102/7/2684/1691680/h81903002684.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730103

30 December 2023

http://ashpublications.org/blood/article-pdf/102/7/2684/1691680/h81903002684.pdf

Portable Document Format

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

2684-2691

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Current drug therapy for multiple myeloma

2

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

The treatment of multiple myeloma

3

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

4

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

High-dose chemotherapy and autologous bone marrow transplantation for myeloma.

5

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

8

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Standard therapy versus autologous transplantation in multiple myeloma

9

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Randomized trial experience of the Intergroupe Francophone du Myélome

11

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

12

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

The toxicity of the bone seeking radionuclides.

18

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach

21

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

23

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.

26

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Regimen-related toxicity in patients undergoing bone marrow transplantation

31

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

32

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Radiation nephropathy after bone marrow transplantation

34

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Bone marrow transplant nephropathy: radiation nephritis revisited

35

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Radiation nephritis. Clinical manifestations and pathophysiologic mechanisms

36

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy

39

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

41

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

42

1 reference

10.1182/BLOOD-2002-10-3250

https://api.crossref.org/works/10.1182/BLOOD-2002-10-3250

30 December 2023

Identifiers

10.1182/BLOOD-2002-10-3250

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44429171&oldid=2098416095"